Literature DB >> 30821391

A critical appraisal and implications of the new National Institute for Health and Care Excellence guideline on dupilumab for treating moderate-to-severe atopic eczema.

S Weidinger1, C Apfelbacher2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30821391     DOI： 10.1111/bjd.17329

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN： 0007-0963            Impact factor:   9.302


× No keyword cloud information.
  1 in total

1.  [Quality of care for patients with atopic dermatitis in Germany-no improvements in indicators after ten years].

Authors:  A Langenbruch; N Mohr; F Abeck; J Schmitt; S Ständer; T Werfel; D Thaçi; S Weidinger; M Augustin
Journal:  Hautarzt       Date:  2021-09-20       Impact factor: 0.751
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.